Literature DB >> 25799212

Voriconazole-associated visual disturbances and hallucinations.

Gulsum Iclal Bayhan1, Mesut Garipardic2, Kamuran Karaman2, Sinan Akbayram2.   

Abstract

Voriconazole is a second-generation azole widely used for the prevention and treatment of fungal infection in leukemia patients. Voriconazole is considered the primary antifungal agent for invasive aspergillosis. We report a case of 16-year-old girl who developed visual disturbance and visual and auditory hallucinations after intravenous voriconazole treatment for invasive pulmonary aspergillosis. Due to the visual hallucinations and visual disturbance began acutely and shortly after the initiation of voriconazole, and no other cause could be determined, the symptoms were considered to be the side effects of voriconazole. Simultaneous development of visual side effects and hallucinations rarely have been reported before.

Entities:  

Keywords:  Color discrimination; hallucinations; visual disturbance; voriconazole

Mesh:

Substances:

Year:  2015        PMID: 25799212     DOI: 10.3109/15569527.2015.1020544

Source DB:  PubMed          Journal:  Cutan Ocul Toxicol        ISSN: 1556-9527            Impact factor:   1.820


  5 in total

1.  The discovery of potential phosphopantetheinyl transferase Ppt2 inhibitors against drug-resistant Candida albicans.

Authors:  Ling-Ning Meng; Jin-Yan Liu; Yu-Ting Wang; Shuai-Shuai Ni; Ming-Jie Xiang
Journal:  Braz J Microbiol       Date:  2020-06-18       Impact factor: 2.476

Review 2.  Potential Targets for Antifungal Drug Discovery Based on Growth and Virulence in Candida albicans.

Authors:  Xiuyun Li; Yinglong Hou; Longtao Yue; Shuyuan Liu; Juan Du; Shujuan Sun
Journal:  Antimicrob Agents Chemother       Date:  2015-07-20       Impact factor: 5.191

3.  Voriconazole Induced Hallucinations and Visual Disturbances in a Female Child: A Case Report and Literature Review.

Authors:  Rujiang Zheng; Yu Li; Chuyi Guo; Yuxin Pei; Zhiyong Ke; Libin Huang
Journal:  Front Pediatr       Date:  2021-04-23       Impact factor: 3.418

Review 4.  Chronic Pulmonary Aspergillosis-Where Are We? and Where Are We Going?

Authors:  Gemma E Hayes; Lilyann Novak-Frazer
Journal:  J Fungi (Basel)       Date:  2016-06-07

Review 5.  Candida Infections and Therapeutic Strategies: Mechanisms of Action for Traditional and Alternative Agents.

Authors:  Giselle C de Oliveira Santos; Cleydlenne C Vasconcelos; Alberto J O Lopes; Maria do S de Sousa Cartágenes; Allan K D B Filho; Flávia R F do Nascimento; Ricardo M Ramos; Emygdia R R B Pires; Marcelo S de Andrade; Flaviane M G Rocha; Cristina de Andrade Monteiro
Journal:  Front Microbiol       Date:  2018-07-03       Impact factor: 5.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.